Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Plummer JD, Postnikoff SD, Tyler JK, Johnson JE. Selenium supplementation inhibits IGF-1 signaling and confers methionine restriction-like healthspan benefits to mice. Elife. 2021;10.

Magro CM, Mulvey J, Kubiak J, Mikhail S, Suster D, A Crowson N, et al. Severe COVID-19: A multifaceted viral vasculopathy syndrome. Ann Diagn Pathol. 2021;50:151645.

Mitchell KF, McElvania E, Wallace MA, Droske LE, Robertson AE, Westblade LF, et al. Evaluating the Rapid Emergence of Daptomycin Resistance in : a Multicenter Study. J Clin Microbiol. 2021;59(4).

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.

Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2021.

Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141-150.

Fragliasso V, Tameni A, Inghirami G, Mularoni V, Ciarrocchi A. Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. Front Oncol. 2021;11:643620.

Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials. 2021;22(1):323.

Velu P, Craney A, Ruggiero P, Sipley J, Cong L, Hissong EM, et al. Rapid Implementation of Severe Acute Respiratory Syndrome Coronavirus 2 Emergency Use Authorization RT-PCR Testing and Experience at an Academic Medical Institution. J Mol Diagn. 2021;23(2):149-158.

Cho C, Hilden P, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, et al. Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. Adv Cell Gene Ther. 2021;4(1).